These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31346052)

  • 21. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum omega-3 polyunsaturated fatty acid and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Zhu QQ; Lou DJ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ; Li D
    Zhonghua Nei Ke Za Zhi; 2010 Apr; 49(4):305-8. PubMed ID: 20627036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathogenesis of non-alcoholic fatty liver and potential therapeutic targets].
    Crespo J; Cayón A; Pons-Romero F
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():15-23. PubMed ID: 15195530
    [No Abstract]   [Full Text] [Related]  

  • 25. [Glucose and lipid metabolism by the liver].
    Ishida T
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1850-4. PubMed ID: 16223145
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies on the liver in diabetes mellitus. II. The significance of fatty metamorphosis and its correlation with insulin sensitivity.
    ZIMMERMAN HJ; MacMURRAY FG; RAPPAPORT H; ALPERT LK
    J Lab Clin Med; 1950 Dec; 36(6):922-8. PubMed ID: 14795025
    [No Abstract]   [Full Text] [Related]  

  • 27. [Abdominal obesity: metabolic complications and consequences for the liver].
    De Vries AP; Bakker SJ; Gans RO
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1910-1. PubMed ID: 11605319
    [No Abstract]   [Full Text] [Related]  

  • 28. [THE LIVER IN DIABETES MELLITUS].
    STROHMEYER G; BECKER K
    Internist (Berl); 1964 Mar; 5():106-11. PubMed ID: 14175268
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycosphingolipids and insulin resistance.
    Aerts JM; Boot RG; van Eijk M; Groener J; Bijl N; Lombardo E; Bietrix FM; Dekker N; Groen AK; Ottenhoff R; van Roomen C; Aten J; Serlie M; Langeveld M; Wennekes T; Overkleeft HS
    Adv Exp Med Biol; 2011; 721():99-119. PubMed ID: 21910085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal muscle ceramides and daily fat oxidation in obesity and diabetes.
    Broskey NT; Obanda DN; Burton JH; Cefalu WT; Ravussin E
    Metabolism; 2018 May; 82():118-123. PubMed ID: 29307520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The path to insulin resistance: paved with ceramides?
    Zierath JR
    Cell Metab; 2007 Mar; 5(3):161-3. PubMed ID: 17339023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceramides mediate cigarette smoke-induced metabolic disruption in mice.
    Thatcher MO; Tippetts TS; Nelson MB; Swensen AC; Winden DR; Hansen ME; Anderson MC; Johnson IE; Porter JP; Reynolds PR; Bikman BT
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(10):E919-27. PubMed ID: 25269485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis.
    Xia JY; Holland WL; Kusminski CM; Sun K; Sharma AX; Pearson MJ; Sifuentes AJ; McDonald JG; Gordillo R; Scherer PE
    Cell Metab; 2015 Aug; 22(2):266-278. PubMed ID: 26190650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different susceptibility to insulin resistance and fatty liver depending on the combination of TNF-α C-857T and adiponectin G+276T gene polymorphisms in Japanese subjects with type 2 diabetes.
    Ohara M; Maesawa C; Takebe N; Takahashi T; Yamashina M; Ono M; Matsui M; Sasai T; Honma H; Nagasawa K; Fujiwara F; Kajiwara T; Taneichi H; Takahashi K; Satoh J
    Tohoku J Exp Med; 2012 Feb; 226(2):161-9. PubMed ID: 22327199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. El papel de los ácidos grasos libres en la resistencia a la insulina.
    Vázquez-Jiménez JG; Roura-Guiberna A; Jiménez-Mena LR; Olivares-Reyes JA
    Gac Med Mex; 2017; 153(7):852-863. PubMed ID: 29414963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
    Byrne CD; Targher G
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of the brain in the regulation of metabolism and energy expenditure: the central role of insulin, and insulin resistance of the brain].
    Halmos T; Suba I
    Orv Hetil; 2011 Jan; 152(3):83-91. PubMed ID: 21205607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uric Acid as a Cause of the Metabolic Syndrome.
    King C; Lanaspa MA; Jensen T; Tolan DR; Sánchez-Lozada LG; Johnson RJ
    Contrib Nephrol; 2018; 192():88-102. PubMed ID: 29393133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance.
    Kelley DE; McKolanis TM; Hegazi RA; Kuller LH; Kalhan SC
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E906-16. PubMed ID: 12959938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans.
    Chung JO; Koutsari C; Blachnio-Zabielska AU; Hames KC; Jensen MD
    Diabetes; 2017 Aug; 66(8):2082-2091. PubMed ID: 28483801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.